Leap Therapeutics Inc Cash Flow Conversion Efficiency
Leap Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Leap Therapeutics Inc (LPTX) has a cash flow conversion efficiency ratio of -6.045x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.29 Million) by net assets ($2.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Leap Therapeutics Inc (2012–2024)
Cash flow conversion efficiency of Leap Therapeutics Inc from 2012 to 2024. This chart illustrates how Leap Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Leap Therapeutics Inc stock price for real-time trading data and today's change.
Leap Therapeutics Inc Cash Flow Conversion Ratio Explained
Leap Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Leap Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Leap Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Leap Therapeutics Inc (LPTX) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chongkundang
KO:001630
|
0.008x |
|
INNATE PHARMA SP.ADR/1
F:IDDA
|
N/A |
|
Dohwa Engin
KO:002150
|
-0.066x |
|
Gabelli Global Utility & Income Tr
NYSE MKT:GLU
|
N/A |
|
Winchester Bancorp, Inc. Common Stock
NASDAQ:WSBK
|
0.011x |
|
Epileds Technologies Inc
TW:4956
|
0.021x |
|
Arcticzymes Technologies ASA
OL:AZT
|
0.023x |
|
American Resources Corp Class A
NASDAQ:AREC
|
-0.127x |
Annual Cash Flow Conversion Efficiency for Leap Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Leap Therapeutics Inc from 2012 to 2024. Review Leap Therapeutics Inc (LPTX) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $35.05 Million | $-60.30 Million | -1.720x | -136.49% |
| 2023-12-31 | $60.14 Million | $-43.75 Million | -0.728x | +18.95% |
| 2022-12-31 | $54.64 Million | $-49.04 Million | -0.898x | -175.43% |
| 2021-12-31 | $107.89 Million | $-35.16 Million | -0.326x | +15.38% |
| 2020-12-31 | $67.41 Million | $-25.96 Million | -0.385x | -102.50% |
| 2019-12-31 | $-1.75 Million | $-26.90 Million | 15.381x | +642.10% |
| 2018-12-31 | $9.18 Million | $-26.03 Million | -2.837x | -42.49% |
| 2017-12-31 | $11.12 Million | $-22.14 Million | -1.991x | -- |
| 2016-12-31 | $0.00 | $-25.34 Million | x | -- |
| 2015-12-31 | $26.87 Million | $-19.58 Million | -0.729x | -86.90% |
| 2014-12-31 | $46.21 Million | $-18.02 Million | -0.390x | +26.38% |
| 2013-12-31 | $18.77 Million | $-9.94 Million | -0.530x | +8.14% |
| 2012-12-31 | $13.10 Million | $-7.55 Million | -0.577x | -- |
About Leap Therapeutics Inc
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-… Read more